Compugen Expands Deal with Bristol Myers Squibb with Phase 1b Combo Study of COM701 with Opdivo

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study designed to assess COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® in selected cancer indications. Study initiation is expected in the second quarter of 2021.

https://www.prnewswire.com/news-releases/compugen-expands-clinical-collaboration-agreement-with-bristol-myers-squibb-with-phase-1b-combination-study-of-com701-with-opdivo-301232339.html